Photo illustration of two people Kiersten (right) with long hair and a blazer and John wearing a button down collar shirt, against a green and dark purple background.
Illustration: Hyacinth Empinado/STAT; Photos: Courtesy DCVC Bio

By Allison DeAngelis

Sept. 30, 2024

Biotech Startups and Venture Capital Reporter

DCVC Bio, a Silicon Valley area investment firm launched six years ago by a group of tech, bio, and agriculture investors, has raised a new $400 million fund, it told STAT exclusively. 

This is the third fund DCVC Bio has raised. It came in ahead of the original $350 million goal, according to executives. 

advertisement

The announcement makes DCVC Bio one of a select number of biotech VCs to raise new pools of capital this year. Biotech investors raised 53 funds last year and 85 funds in 2022, but halfway through this year, they had raised just 15 funds. (Both ARCH Venture Partners and Flagship Pioneering have announced new fundraisings since then.) 

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
,
Submit a correction requestReprints

  1. Allison DeAngelis

    Biotech Startups and Venture Capital Reporter

    Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.